These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 1968871)
1. Effects of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis. Podda M; Ghezzi C; Battezzati PM; Crosignani A; Zuin M; Roda A Gastroenterology; 1990 Apr; 98(4):1044-50. PubMed ID: 1968871 [TBL] [Abstract][Full Text] [Related]
2. Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: a dose-response study. Crosignani A; Battezzati PM; Setchell KD; Camisasca M; Bertolini E; Roda A; Zuin M; Podda M Hepatology; 1991 Feb; 13(2):339-44. PubMed ID: 1671665 [TBL] [Abstract][Full Text] [Related]
3. Effects of ursodeoxycholic acid (ursodiol) treatment on chronic viral hepatitis in heart transplant patients: results of a prospective, double-blind, placebo-randomized study. Cadranel JF; Di Martino V; Dorent R; Bernard B; Hoang C; Myara A; Pauwels A; Ghoussoub JJ; Perrin M; Grippon P; Thabut D; Trivin F; Huraux JM; Gandjbakhch I; Opolon P; Lunel F Transplantation; 2003 Apr; 75(7):977-82. PubMed ID: 12698083 [TBL] [Abstract][Full Text] [Related]
4. Effect of ursodeoxycholic acid in chronic hepatitis and primary biliary cirrhosis. Osuga T; Tanaka N; Matsuzaki Y; Aikawa T Dig Dis Sci; 1989 Dec; 34(12 Suppl):49S-51S. PubMed ID: 2574657 [TBL] [Abstract][Full Text] [Related]
5. Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double-blind controlled study. Rolandi E; Franceschini R; Cataldi A; Cicchetti V; Carati L; Barreca T Eur J Clin Pharmacol; 1991; 40(5):473-6. PubMed ID: 1679391 [TBL] [Abstract][Full Text] [Related]
6. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis. Matsuzaki Y; Tanaka N; Osuga T; Aikawa T; Shoda J; Doi M; Nakano M Am J Gastroenterol; 1990 Jan; 85(1):15-23. PubMed ID: 1967512 [TBL] [Abstract][Full Text] [Related]
7. Ursocholic acid, a hydrophilic bile acid, fails to improve liver function parameters in primary biliary cirrhosis: comparison with ursodeoxycholic acid. Batta AK; Salen G; Abroon J Am J Gastroenterol; 1997 Jun; 92(6):1035-7. PubMed ID: 9177526 [TBL] [Abstract][Full Text] [Related]
8. Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis: effect of ursodeoxycholic treatment. Chretien Y; Poupon R; Gherardt MF; Chazouilleres O; Labbe D; Myara A; Trivin F Gut; 1989 Aug; 30(8):1110-5. PubMed ID: 2767508 [TBL] [Abstract][Full Text] [Related]
9. Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis. Batta AK; Salen G; Arora R; Shefer S; Tint GS; Abroon J; Eskreis D; Katz S Hepatology; 1989 Oct; 10(4):414-9. PubMed ID: 2777202 [TBL] [Abstract][Full Text] [Related]
10. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. Colombo C; Setchell KD; Podda M; Crosignani A; Roda A; Curcio L; Ronchi M; Giunta A J Pediatr; 1990 Sep; 117(3):482-9. PubMed ID: 2391610 [TBL] [Abstract][Full Text] [Related]
11. A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis. Oka H; Toda G; Ikeda Y; Hashimoto N; Hasumura Y; Kamimura T; Ohta Y; Tsuji T; Hattori N; Namihisa T Gastroenterol Jpn; 1990 Dec; 25(6):774-80. PubMed ID: 1980654 [TBL] [Abstract][Full Text] [Related]
12. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Takano S; Ito Y; Yokosuka O; Ohto M; Uchiumi K; Hirota K; Omata M Hepatology; 1994 Sep; 20(3):558-64. PubMed ID: 7521313 [TBL] [Abstract][Full Text] [Related]
13. The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis. A 12-month double-blind, placebo-controlled trial. Attili AF; Rusticali A; Varriale M; Carli L; Repice AM; Callea F J Hepatol; 1994 Mar; 20(3):315-20. PubMed ID: 7912249 [TBL] [Abstract][Full Text] [Related]
14. Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration. Nakagawa M; Colombo C; Setchell KD Hepatology; 1990 Aug; 12(2):322-34. PubMed ID: 2391071 [TBL] [Abstract][Full Text] [Related]
15. Bile acid-induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acids. Attili AF; Angelico M; Cantafora A; Alvaro D; Capocaccia L Med Hypotheses; 1986 Jan; 19(1):57-69. PubMed ID: 2871479 [TBL] [Abstract][Full Text] [Related]
16. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Omata M; Yoshida H; Toyota J; Tomita E; Nishiguchi S; Hayashi N; Iino S; Makino I; Okita K; Toda G; Tanikawa K; Kumada H; Gut; 2007 Dec; 56(12):1747-53. PubMed ID: 17573387 [TBL] [Abstract][Full Text] [Related]
17. [Effect of post-liver transplantation administration of ursodeoxycholic acid on serum liver tests and biliary complications: a randomized clinical trial]. Wang S; Tang M; Chen G; Xu J; Zhong L; Wang Z; Deng G; Xing T; Lu L; Peng Z Zhonghua Gan Zang Bing Za Zhi; 2014 Jul; 22(7):529-35. PubMed ID: 25203806 [TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy and side effects of ursodeoxycholic and chenodeoxycholic acids in dissolving gallstones. A double-blind controlled study. Fromm H; Roat JW; Gonzalez V; Sarva RP; Farivar S Gastroenterology; 1983 Dec; 85(6):1257-64. PubMed ID: 6354826 [TBL] [Abstract][Full Text] [Related]